MA40709A1 - Dérivé du glucagon à stabilité améliorée - Google Patents

Dérivé du glucagon à stabilité améliorée

Info

Publication number
MA40709A1
MA40709A1 MA40709A MA40709A MA40709A1 MA 40709 A1 MA40709 A1 MA 40709A1 MA 40709 A MA40709 A MA 40709A MA 40709 A MA40709 A MA 40709A MA 40709 A1 MA40709 A1 MA 40709A1
Authority
MA
Morocco
Prior art keywords
glucagon
glucagon derivative
improved stability
present
peptide
Prior art date
Application number
MA40709A
Other languages
English (en)
Other versions
MA40709B1 (fr
Inventor
Sung Youb Jung
Se Chang Kwon
Jung Kuk Kim
Jong Min Lee
Sang Yun Kim
Sung Min Bae
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA40709A1 publication Critical patent/MA40709A1/fr
Publication of MA40709B1 publication Critical patent/MA40709B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un nouveau peptide dérivé du glucagon, ainsi qu'une composition destinée à la prévention ou au traitement de l'hypoglycémie et de l'obésité, comprenant le peptide en tant que principe actif. Le dérivé de glucagon de la présente invention présente une activité maintenue dans le temps contre les récepteurs du glucagon et présente des propriétés physiques améliorées en raison d'une modification de son point isoélectrique, et est ainsi capable d'améliorer l'utilisation conforme
MA40709A 2014-12-30 2015-12-30 Dérivé du glucagon à stabilité améliorée MA40709B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140193800 2014-12-30
PCT/KR2015/014422 WO2016108586A1 (fr) 2014-12-30 2015-12-30 Dérivé du glucagon à stabilité améliorée

Publications (2)

Publication Number Publication Date
MA40709A1 true MA40709A1 (fr) 2017-12-29
MA40709B1 MA40709B1 (fr) 2019-07-31

Family

ID=56284642

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40709A MA40709B1 (fr) 2014-12-30 2015-12-30 Dérivé du glucagon à stabilité améliorée

Country Status (29)

Country Link
US (1) US11135271B2 (fr)
EP (2) EP3241841A4 (fr)
JP (2) JP6797122B2 (fr)
KR (1) KR102291020B1 (fr)
CN (1) CN107636009B (fr)
AR (1) AR103322A1 (fr)
AU (1) AU2015372818A1 (fr)
CA (1) CA2972748A1 (fr)
CL (1) CL2017001718A1 (fr)
CO (1) CO2017006308A2 (fr)
CR (1) CR20170293A (fr)
DO (1) DOP2017000156A (fr)
EA (1) EA035527B1 (fr)
EC (1) ECSP17040923A (fr)
ES (1) ES2976562T3 (fr)
GT (1) GT201700150A (fr)
HK (1) HK1248713A1 (fr)
IL (2) IL253206B (fr)
MA (1) MA40709B1 (fr)
MX (1) MX2017008569A (fr)
MY (1) MY185334A (fr)
PE (2) PE20230304A1 (fr)
PH (1) PH12017501222A1 (fr)
SG (1) SG11201705376SA (fr)
TN (1) TN2017000271A1 (fr)
TW (1) TW201639878A (fr)
UA (1) UA126960C2 (fr)
WO (1) WO2016108586A1 (fr)
ZA (1) ZA201705015B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US10981967B2 (en) 2015-12-31 2021-04-20 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
US11142559B2 (en) 2016-06-29 2021-10-12 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR112019016077A2 (pt) 2017-02-03 2020-03-31 Hanmi Pharm. Co., Ltd. Conjugado da fórmula 1, método para preparar o conjugado, preparação de atuação longa, preparação para prevenir ou tratar diabetes e método para tratar diabetes
CN111511910A (zh) * 2017-12-22 2020-08-07 韩美药品株式会社 具有新颖结构的治疗酶融合蛋白及其用途
CN111936159A (zh) * 2018-01-23 2020-11-13 Xeris药物公司 使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症
US20220064248A1 (en) 2018-12-21 2022-03-03 HANMl PHARM. CO., LTD Pharmaceutical composition including insulin and glucagon
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
IL298396A (en) 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of a glucagon derivative
CA3186097A1 (fr) 2020-07-15 2022-01-20 Jung Kuk Kim Utilisation therapeutique d'un derive du glucagon ou d'un conjugue de celui-ci pour une maladie hepatique
CN117157094A (zh) 2021-04-09 2023-12-01 韩美药品株式会社 包括胰高血糖素衍生物的用于预防或治疗慢性肾病的药物组合物
KR20230095666A (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
CA2518336A1 (fr) 2003-03-19 2004-11-04 Eli Lilly And Company Composes glp-1 a liaison polyethylene glycol
JP4870569B2 (ja) 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
CA2677932A1 (fr) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Co-agonistes des recepteurs du glucagon/glp-1
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
SG178797A1 (en) 2007-06-19 2012-03-29 Otsuka Chemical Co Ltd Oligosaccharide chain added glp-1 peptide
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CL2009001425A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
CA2727161A1 (fr) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Analogues de glucagon presentant des tampons de ph physiologique presentant une solubilite et une stabilite ameliorees
WO2010096052A1 (fr) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
IN2012DN00377A (fr) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
ES2537287T3 (es) 2009-07-13 2015-06-05 Zealand Pharma A/S Análogos de glucagón acilados
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EA026384B1 (ru) * 2010-01-20 2017-04-28 Зилэнд Фарма А/С Лечение заболеваний сердца
RU2559320C2 (ru) * 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
MX2012013005A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g.
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
CA3134906A1 (fr) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Substances pharmaceutiques peptidiques ameliorees pour la resistance a l'insuline
ES2692187T3 (es) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
KR101577734B1 (ko) * 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
WO2013004983A1 (fr) 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
CA2847246A1 (fr) * 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon presentant une action sur les recepteurs aux glucocorticoides
PL2864350T3 (pl) 2012-06-21 2019-01-31 Indiana University Research And Technology Corporation Analogi glukagonu wykazujące aktywność wobec receptora GIP
KR20150023013A (ko) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 수용체 활성을 나타내는 글루카곤 유사체
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
WO2014049610A2 (fr) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon
WO2014073842A1 (fr) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Formulation liquide d'un conjugué protéique comprenant l'oxyntomoduline et un fragment d'immunoglobuline
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
EP3653649A1 (fr) 2012-11-20 2020-05-20 Mederis Diabetes, LLC Produits pharmaceutiques peptidiques améliorés pour la résistance à l'insuline
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
MX362275B (es) * 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
EP3206710B1 (fr) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Conjugués d'insuline-incrétines
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
EA035527B1 (ru) 2014-12-30 2020-06-30 Ханми Фарм. Ко., Лтд. Производные глюкагона с улучшенной стабильностью
PE20240215A1 (es) * 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物
KR20170080521A (ko) 2015-12-31 2017-07-10 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11261227B2 (en) 2015-06-30 2022-03-01 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11667688B2 (en) 2015-06-30 2023-06-06 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US10981967B2 (en) 2015-12-31 2021-04-20 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
US11332508B2 (en) 2015-12-31 2022-05-17 Hanmi Pharm. Co., Ltd. Triple glucagon/GLP-1/GIP receptor agonist
US11142559B2 (en) 2016-06-29 2021-10-12 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof

Also Published As

Publication number Publication date
NZ733464A (en) 2024-01-26
SG11201705376SA (en) 2017-08-30
CR20170293A (es) 2017-11-03
ES2976562T3 (es) 2024-08-05
US11135271B2 (en) 2021-10-05
EP3575314B1 (fr) 2024-02-14
EP3575314A2 (fr) 2019-12-04
BR112017014205A2 (pt) 2018-03-06
KR102291020B1 (ko) 2021-08-20
KR20160082482A (ko) 2016-07-08
IL253206B (en) 2021-10-31
JP2018504901A (ja) 2018-02-22
CN107636009B (zh) 2021-04-16
EP3575314C0 (fr) 2024-02-14
JP7079301B2 (ja) 2022-06-01
TW201639878A (zh) 2016-11-16
CN107636009A (zh) 2018-01-26
UA126960C2 (uk) 2023-03-01
ZA201705015B (en) 2018-04-25
EP3241841A4 (fr) 2018-10-17
MX2017008569A (es) 2017-10-20
JP6797122B2 (ja) 2020-12-09
EP3575314A3 (fr) 2020-01-22
TN2017000271A1 (en) 2018-10-19
CA2972748A1 (fr) 2016-07-07
PE20171154A1 (es) 2017-08-16
AR103322A1 (es) 2017-05-03
NZ770767A (en) 2024-04-26
IL281375B (en) 2021-10-31
CO2017006308A2 (es) 2017-09-29
IL281375A (en) 2021-04-29
WO2016108586A1 (fr) 2016-07-07
DOP2017000156A (es) 2017-10-15
HK1248713A1 (zh) 2018-10-19
MY185334A (en) 2021-05-06
AU2015372818A1 (en) 2017-07-27
MA40709B1 (fr) 2019-07-31
JP2020188819A (ja) 2020-11-26
PE20230304A1 (es) 2023-02-13
CL2017001718A1 (es) 2018-01-12
PH12017501222A1 (en) 2018-01-15
US20170360892A1 (en) 2017-12-21
IL253206A0 (en) 2017-08-31
EA201791333A1 (ru) 2017-12-29
EA035527B1 (ru) 2020-06-30
EP3241841A1 (fr) 2017-11-08
ECSP17040923A (es) 2017-12-01
GT201700150A (es) 2018-12-12

Similar Documents

Publication Publication Date Title
MA40709B1 (fr) Dérivé du glucagon à stabilité améliorée
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
AU2018260800B2 (en) Hepcidin analogues and uses therof
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201890343A1 (ru) Быстродействующие инсулиновые композиции
EA201590058A1 (ru) Аналоги глюкагона
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690606A1 (ru) Аналоги глюкагона
EA201791617A1 (ru) Аналоги амилина
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201990360A1 (ru) Аналоги амилина
EA201890570A1 (ru) [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль
EA201690159A1 (ru) Способы и композиции для лечения рака
FR3061856B1 (fr) Utilisations therapeutiques d'une poudre d'insectes
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
EA201791005A1 (ru) Улучшенные антитела против il-6
BR112016028227A2 (pt) método para redução de imunogenicidade de proteína e peptídeo
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2018001343A1 (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование